Skip to content


Perjeta (pertuzumab) is an antibody pharmaceutical. Pertuzumab was first approved as Perjeta on 2012-06-08. It is used to treat breast neoplasms in the USA. It has been approved in Europe to treat breast neoplasms. The pharmaceutical is active against receptor tyrosine-protein kinase erbB-2.
Trade Name Perjeta
Common Name Pertuzumab
Indication breast neoplasms
Drug Class Monoclonal antibodies: humanized, tumors as target
Get full access now